Curated News
By: NewsRamp Editorial Staff
September 16, 2026
SS Innovations' SSi Mantra Hits 238 Installs, 14,103 Procedures
TLDR
- SS Innovations grew SSi Mantra installations 42 percent to 238 and procedures 79 percent, positioning SSII for FDA and EU market expansion.
- SS Innovations reported 238 SSi Mantra installations, 14,103 procedures, 1,500 trained physicians, and pending FDA 510(k) and EU CE marking reviews.
- SS Innovations expands robotic surgery to 12 countries, enabling pediatric kidney procedures on infants and improving global access to minimally invasive care.
- SS Innovations now has 188 telesurgeries and a robotic kidney procedure on a 45-day-old infant, showing how surgical robots cross borders.
Impact - Why it Matters
This news matters because it demonstrates the accelerating adoption of robotic surgery in emerging markets and beyond, potentially broadening access to minimally invasive procedures. SS Innovations' growth in installations and procedures, especially in pediatric cases and telesurgery, signals a shift toward more advanced, accessible surgical care. Regulatory milestones on the horizon could further propel the company's market presence, benefiting patients and investors alike.
Summary
SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, is reporting continued growth in the use of its SSi Mantra surgical robotic system, with the company’s installed base and procedure count increasing as it expands into new countries and surgical applications. In an update issued September 10, the company said 238 SSi Mantra systems were installed as of September 8, up 42% from 168 at the end of 2025. Procedures performed with the system reached 14,103, representing a 79% increase from 7,885 at year-end. The installed base now spans 12 countries, following recent launches in Colombia and Sri Lanka and further international expansion.
The company also said approximately 1,500 physicians have now been trained on SSi Mantra, which has been used in a growing range of procedures. Pediatric applications continue to expand, including a robotic kidney procedure performed on a 45-day-old infant in India using 5-millimeter instruments. SS Innovations reported 188 cumulative robotic telesurgeries as of August 31, alongside long-distance procedures connecting surgeons and patients across countries. Looking ahead, the company expects FDA review of its 510(k) submission by the end of Q1 2027 and believes EU CE marking for SSi Mantra could be obtained by the end of 2026. For investors seeking more information, the full announcement is available via Read More>>.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, SS Innovations' SSi Mantra Hits 238 Installs, 14,103 Procedures
